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Objectives Our objective was to test the performance of CA125 in classifying serum samples from a 2 
cohort of malignant and benign ovarian cancers and age-matched healthy controls and to assess 3 
whether combining information from MALDI-TOF profiling could improve diagnostic performance. 4 
Methods/Materials Serum samples from women with ovarian neoplasms and healthy volunteers were 5 
subjected to CA125 assay and MALDI-TOF MS profiling. Models were built from training datasets 6 
using discriminatory MALDI MS peaks in combination with CA125 values and tested their ability to 7 
classify blinded test samples. These were compared to models using CA125 threshold levels from 193 8 
patients with ovarian cancer, 290 with benign neoplasm and 2236 post-menopausal healthy controls. 9 
Results Using a CA125 cut-off of 30 U/mL, an overall sensitivity of 94.8% (96.6% specificity) was 10 
obtained when comparing malignancies vs. healthy post-menopausal controls, while a cut-off of 65 11 
U/mL provided a sensitivity of 83.9% (99.6% specificity). High classification accuracies were obtained 12 
for early-stage cancers (93.5% sensitivity). Reasons for high accuracies include recruitment bias, 13 
restriction to post-menopausal women and inclusion of only primary invasive epithelial ovarian cancer 14 
cases. The combination of MS profiling information with CA125 did not significantly improve the 15 
specificity/accuracy compared to classifications based on CA125 alone.  16 
Conclusions We report unexpectedly good performance of serum CA125 using threshold classification 17 
in discriminating healthy controls and women with benign masses from those with invasive ovarian 18 
cancer. This highlights the dependence of diagnostic tests on the characteristics of the study population 19 
and the crucial need for authors to provide sufficient relevant details to allow comparison. Our study 20 
also shows that MS profiling information adds little to diagnostic accuracy. This finding is in contrast 21 
with other reports and shows the limitations of serum MS profiling for biomarker discovery and as a 22 





Ovarian cancer is the leading cause of death from gynaecologic malignancy in the western world which 2 
is mainly attributable to its diagnosis at an advanced stage (1, 2). This suggests that detecting ovarian 3 
cancer at an earlier stage may improve survival. Crucial to early detection is the identification of 4 
accurate biomarkers. Serum CA125 is the most extensively assessed biomarker for ovarian cancer with 5 
elevated levels of CA125 found in >90% of patients with advanced disease. However, CA125 has been 6 
shown to lack sensitivity (50-60%) for early-stage disease detection (1, 3-8) and its expression is not 7 
specific to malignant ovarian cancers (9). Indeed, CA125 can be elevated in women with benign 8 
gynaecological conditions such as ovarian cysts, endometriosis, and uterine fibroids, as well as in other 9 
cancers (breast, bladder, pancreatic, liver, lung) (10). Efforts have therefore been made to identify 10 
additional biomarkers to complement CA125. 11 
Over the last two decades, dozens of new biomarkers of ovarian carcinomas have been proposed, 12 
with combinations of these biomarkers with or without CA125 reported to significantly increase the 13 
accuracy in detecting ovarian cancer at both early and late stages (6, 8, 11-16). Some of the multiple marker 14 
panels achieved the important benchmark value of >99.6% specificity that is required to achieve a 15 
positive predictive value of 10% (for an incidence rate of 40 per 100,000 women). However, this was 16 
accompanied by a fall in sensitivity values to <60% for early-stage and <77% for late-stage cancer (16). 17 
In the context of ovarian cancer screening, CA125 interpreted using a Risk of Ovarian Cancer 18 
algorithm has a high sensitivity and specificity for detecting primary invasive ovarian and tubal 19 
malignancies. For multimodal screening using annual CA125 screening with transvaginal ultrasound 20 
scan as a second-line test, the sensitivity for primary ovarian and tubal malignancies was 89.4% at a 21 
specificity of 99.8% (17). Whilst the performance of screening strategies has greatly improved in recent 22 
years, the need for additional screening modalities providing both high sensitivity and specificity 23 
remains. Likewise, the differential diagnosis of symptomatic patients would also benefit from improved 24 
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and simpler tests. With this in mind, the objective of this study was to evaluate whether combinations 1 
of serum CA125 and mass spectrometry (MS) profiling data could enhance the identification of ovarian 2 




Material and Methods 1 
Subjects, sample collection and handling 2 
The study was approved by the local ethics committee (MREC 05/Q0505/58) and written informed 3 
consent was obtained from all donors. Women were recruited to the UK Ovarian Cancer Population 4 
Study (UKOPS) from ten NHS Trusts across the UK. Patients were recruited at gynaecological 5 
oncology departments and healthy volunteers were recruited from women attending annual screening in 6 
the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) (17, 18). Supplemental Data 1 7 
provides details on the initial set of subjects, sample collection, transport and storage. For the combined 8 
MS profiling and CA125 assay analyses we used the same sample set as previously reported (19). After 9 
excluding samples with missing CA125 values and those from borderline ovarian cancer cases, the data 10 
from 321 women were used for identifying the best classification models when comparing malignant 11 
vs. healthy and malignant vs. benign. Sixty seven samples were from individuals newly diagnosed with 12 
invasive epithelial ovarian cancer, 84 were from women diagnosed with benign ovarian neoplasm and 13 
170 were from age-matched healthy controls. For model generation and validation, samples were 14 
divided into two training and test sets (see Table 1). Figure 1A shows CA125 assay values across the 15 
groups. For the extended CA125 analysis, CA125 serum levels were evaluated from 2719 women. 16 
Supplemental Data 2 shows the division of this set into the three classes (malignant, benign and 17 
healthy), FIGO stage distribution and average and median age in each class and stage group.   18 
CA125 immunoassays 19 
Samples collected, processed and frozen at the regional centres were transported on dry ice to the UCL 20 
laboratory and thawed. After thawing, samples were mixed by gentle inversion and CA125 analysis 21 
was performed using an electro-chemiluminescence immunoassay (ECLIA) on a Roche Elecsys 2010 22 
analyser (Roche Diagnostics, Burgess Hill, UK). The assay uses monoclonal antibodies OC125 as the 23 
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detection antibody and M11 as the capture antibody (Fujirebio Diagnostics; Oxford Biosystems, 1 
Oxford, UK). 2 
MALDI-TOF MS-based profiling 3 
Samples were processed and analysed in two batches. Samples in each batch were randomized at the 4 
UCL laboratory, thawed and aliquoted into 96-well plates, then transported on dry ice to the BioCentre 5 
at the University of Reading and stored at -80°C. For MS serum polypeptide profiling, samples were 6 
prepared according to previously published methods (19) (20) and profiled using an Ultraflex II MALDI-7 
TOF/TOF mass spectrometer (Bruker Daltonics, Coventry, UK). Various spectral quality control 8 
criteria were implemented with adequate quality assurance for the entire sample preparation process, 9 
data collection and analysis (19) (20). Supplemental Data 3 provides details on sample preparation, data 10 
acquisition and pre-processing. 11 
Data processing and classification 12 
Raw spectral data was processed using algorithms developed in-house (19). Data from the two batch 13 
analyses were combined with corresponding CA125 values and used to construct two training and 14 
blinded test sets for classification (Table 1). Prediction models were constructed for two types of 15 
discrimination independently, malignant vs. healthy and malignant vs. benign, and compared to simple 16 
classification using a CA125 cut-off value of 30 U/mL. Multiple models using the weighted k-nearest 17 
neighbours algorithm (kNN), logical combinations of cut-off rules, cut-off rules for linear combinations 18 
and support vector machine (SVM) with various kernels were applied to subsets of peaks of certain 19 
cardinality (usually a small number). Cross-validation was performed by randomising sample labels in 20 
1,000 iterations and calculating p-values (Monte-Carlo method) for the randomly permuted and 21 
correctly labeled samples. The models performing best on the training sets (all weighted kNN models) 22 
were then validated on the blinded test sets. For calculation of significance of improvement through 23 
addition of MS profiling data, a Monte-Carlo test was applied that measured the chance to get the 24 
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accuracy greater than or equal to the best accuracy achieved on the test set if peak intensities were 1 
reshuffled across samples at the given CA125 accuracy. The p-value was calculated as the proportion 2 
of iterations with accuracy greater than or equal to the accuracy achieved with the best model. For 3 
analysis of the extended sample set using CA125, various cut-off values were tested and ROC analysis 4 
was applied using GraphPad Prism v5.0 software (GraphPad Software Inc., La Jolla, CA, USA). 5 
Peak identification by MALDI-QTOF MS/MS 6 
Peak identifications in this study were obtained by analysing a pool of serum samples on a Premier Q-7 
TOF mass spectrometer (Waters, Manchester, UK) in the MALDI mode using a comparable MALDI 8 






Classification performance using MS profiling data and CA125 values 2 
As shown in our previous study (19), MALDI-TOF MS profiling was robust and reproducible with inter-3 
assay coefficients of variance <15%. Nonetheless, MALDI MS profiling data alone had only limited 4 
diagnostic value for ovarian cancer, particularly when compared with recent reports using multi-5 
biomarker panels (6, 8, 11-17, 21). Consequently, we have evaluated the performance of classification 6 
models derived from the combination of MS profiling and CA125 immunoassay data. 7 
Our first analysis employed randomly selected sets for training and testing as detailed in the upper 8 
part of Table 1. Modelling for the separation of women with invasive epithelial ovarian cancer from 9 
healthy controls revealed that weighted kNN algorithms performed best, with several models 10 
outperforming simple CA125 cut-off classification (at a 30 U/mL threshold) in the training set. Three 11 
models were chosen for validation in the blinded test set selecting each for highest sensitivity, 12 
specificity and quality, respectively. One of these models performed better than CA125 alone in the test 13 
set with an accuracy of 100% (Table 2; upper part), although this improvement was not statistically 14 
significant (p=0.24). Comparison of invasive epithelial ovarian cancer (malignant) and benign cases 15 
showed inferior performance based on overall accuracy and quality in the test set, although several 16 
models outperformed the CA125 cut-off classification in the training set (Table 2; lower part). 17 
This analysis demonstrates that a classification model utilising CA125 values alone using a cut-off 18 
level of 30 U/mL performs extremely well in this sample set. In this specific case, all malignant 19 
samples in the test set had CA125 values >30 U/mL, making it impossible to improve on sensitivity.  20 
Similarly, only one healthy sample had a CA125 value >30 U/mL, giving little space for improvement 21 
in specificity. As a consequence, we reshuffled the training and test set according to two conditions. 22 
First, the ratio between the training and test set was set at ~2:1 for all classes. Second, in both sets each 23 
class had the same ratio of samples above and below 30 U/mL CA125 (lower part of Table 1). 24 
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Modelling analysis using these new training and test sets showed more models were now able to 1 
improve on specificity in comparison to CA125 alone. Nonetheless, the improvement in discriminating 2 
malignant from healthy controls was still limited to a maximum of two additional correctly classified 3 
healthy samples in the test set, whilst sensitivity could not be further improved. Likewise, for 4 
classification of malignant vs. benign cases there was improvement in specificity for many models in 5 
the test set, but none matched the sensitivity when using CA125 alone, limiting overall accuracy (Table 6 
3). Improvement in overall accuracy with the best model, from 76.9% (CA125 cut-off model) to 78.9% 7 
(5 out of 10 model), was not significant (p=0.72).  Furthermore, neither of the discriminatory peaks 8 
(m/z 2755 and 2094) in this model was found in any of the best models obtained from the initial sample 9 
sets. These two peaks were identified as fragments of serum albumin (25-48; Swiss-Prot entry P02768) 10 
and fibrinogen α-chain (605-624; Swiss-Prot entry P02671). Only one peak (m/z 4787) from the 11 
models in Table 3 was also used in the best models from the first analysis (cf. Table 2). 12 
Classification performance using simple CA125 cut-off models 13 
As a consequence of the good performance of CA125 cut-off classification, we further investigated an 14 
extended set of UKOPS samples looking at CA125 alone for classification. This extended set 15 
comprised 2236 healthy controls (median age of 64.31), 290 benign (median age of 57.96) and 193 16 
invasive ovarian cancers (median age of 63.88), of which 48.2% were FIGO stage I (n=74) or II (n=19) 17 
(see Supplemental data 2). In the comparison of malignant and healthy samples, using a 65 U/mL cut-18 
off level, only 10 out of 2236 healthy women had elevated CA125 giving a specificity of 99.6% (95%-19 
CI of 99.1-99.8%) and a sensitivity of 83.9% (95%-CI of 78.0-88.8%). At a 30 U/mL cut-off level, a 20 
sensitivity of 94.8% (95%-CI of 90.7-97.5%) and specificity of 96.6% (95%-CI of 95.5-97.3%) were 21 
obtained. For malignant vs. benign, the 65 U/mL cut-off gave a specificity of 76.2% (95%-CI of 70.9-22 
81.0%) at a sensitivity of 83.9%, whilst a 30 U/mL cut-off gave 53.4% specificity (95%-CI of 47.5-23 
59.3%). The area under the receiver operating characteristic curve (AUROC) for this classification was 24 
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0.877 (p<0.0001; 95%-CI of 0.846-0.908) (Figure 2A). Analysis of early-stage cancer vs. benign 1 
revealed that at the 65 U/mL CA125 threshold, the sensitivity was 77.4% (95%-CI of 67.6-85.5%) and 2 
at 30 U/mL, was 92.5% (95%-CI of 85.1-96.9%). Due to the relatively low number of stage II samples 3 
(n=19), these sensitivity values only changed marginally when only stage I samples (n=74) were used; 4 
the AUROC for stage I vs. benign cancer was 0.842 (p<0.0001; 95%-CI of 0.794-0.891) (Figure 2B) 5 






We have further evaluated our earlier reported MALDI MS profiling study by combining profiling data 2 
with pre-operative CA125 serum levels. The rationale was to explore if this combination could improve 3 
in discriminating healthy women or those with benign masses from women with invasive epithelial 4 
ovarian cancer. Two different training and test sets were employed, one using representative sampling 5 
with respect to CA125 value distribution above and below 30 U/mL. Although improvements in 6 
classification performance for discriminating healthy or benign samples from malignant samples were 7 
apparent in the training sets (compared to a standard 30 U/mL CA125 cut-off classification), only 8 
marginal and statistically insignificant improvement on performance was achieved in the test sets. This 9 
is in keeping with our earlier observation that MS profiling alone is limited in its ability to discriminate 10 
malignant ovarian cancer samples from benign or healthy controls (19). However, the unexpectedly 11 
good performance of the CA125 immunoassay on its own made it virtually impossible to improve on 12 
performance. 13 
We next used an extended set of over 2700 samples to investigate further this better-than-expected 14 
CA125 performance. At a threshold of 65 U/mL CA125, only 10 out of 2236 healthy controls were 15 
misclassified providing a specificity of 99.6%. At a 30 U/mL cut-off, the specificity was 96.6%, while 16 
the sensitivity for correctly identifying malignant samples was 94.8%. For early-stage disease (stage I 17 
& II) the sensitivity was still 92.5% at 30 U/mL and 90.3% at 35 U/mL, and above reported values. It is 18 
also noteworthy that our CA125 classification of early-stage cancer vs. healthy performed as well as, or 19 
better than, classification models based on multiple biomarkers (8, 11, 16). CA125 also showed improved 20 
accuracy for discriminating malignant vs. benign cases compared to recent literature. For example, the 21 
pooled sensitivity of CA125 in a meta-analysis on diagnostic strategies for distinguishing adnexal 22 
masses was 78% at a threshold of 35 U/mL, with individual study sensitivities ranging from 45-100% 23 
(22). For stage I cases alone, comparison with a recent study (12), showed that our sensitivity values are 24 
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more than twice as high for 90%-specificity (54.1%) and 95%-specificity (33.8%) and more than thrice 1 
as high for 98%-specificity (27%). 2 
The high sensitivity of CA125 in this study may reflect the fact that samples were obtained from 3 
women referred to specialist gynaecological cancer centres who may in part have been referred on the 4 
basis of elevated CA125. This is in keeping with a recent report that over-representation of operative 5 
cases, especially from academic facilities, exaggerates the performance of CA125 in regard to 6 
sensitivity and PPV (22).  The good performance may also in part be explained by the exclusion of pre-7 
menopausal women from our cohort, since both sensitivity and specificity of CA125 are consistently 8 
higher in post-menopausal women. This is the rationale underlying restricting participation in ovarian 9 
cancer screening trials such as UKCTOCS (17, 18) to only post-menopausal women. The definition of 10 
malignancy is another factor that can influence test accuracy. In this study, samples were restricted to 11 
those from cases of primary invasive epithelial cancer, the most common ovarian cancers and the main 12 
contributor to the high case fatality ratio associated with the disease. This further increased our 13 
accuracy as we excluded both non-epithelial ovarian malignancies and borderline/low malignant 14 
potential ovarian cancers, both of which are less likely to produce CA125.  Staging of ovarian cancer 15 
and the CA125 immunoassay are other sources for potential bias, but both procedures are relatively 16 
standardised and, therefore, less likely to have contributed to the observed higher accuracies.   17 
In conclusion, we report the unexpectedly good performance of simple serum CA125 threshold 18 
classification in discriminating healthy and benign from malignant samples for the detection of ovarian 19 
cancer. Compared to the data on CA125 assays published so far, a substantially increased accuracy was 20 
obtained. Reasons for this increase include recruitment bias in the specialist gynaecological oncology 21 
centres participating in sample collection, restriction of the study to post-menopausal women and 22 
restricting the definition of ovarian malignancy to primary invasive epithelial cancer. The performance 23 
characteristics of the CA125 immunoassay in our study highlight its dependence on the study 24 
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population and the crucial need for authors to provide sufficient detail on relevant characteristics of 1 
study populations to allow comparisons.  2 
The collection of serum samples and their subsequent handling followed a strict protocol designed 3 
for optimal proteomic profiling with the aim of minimising post-sampling difference due to proteolysis. 4 
However, the combination of CA125 with MS profiling data provided only marginal improvement. 5 
Unfortunately, due to the good performance of CA125 as a discriminatory biomarker, the benefit of 6 
MS profiling to provide additional classification power is difficult to judge. In this context, the 7 
additional benefit of MS profiling should be evaluated in combination with other biomarkers and/or 8 
using study groups where sensitivity values can be improved upon. Here, the MS identification of 9 
proteins of low specificity (serum albumin and fibrinogen α-chain) as the source of potentially 10 






This work was supported by the Medical Research Council through grants G0301107 and G0401619.  2 
Part of this work was undertaken at UCLH/UCL who received a proportion of funding from the 3 





[1] Jacobs IJ, Menon U. Progress and challenges in screening for early detection of ovarian cancer. 2 
Mol Cell Proteomics. 2004;3: 355-66. 3 
[2] Schwartz PE. Current diagnosis and treatment modalities for ovarian cancer. Cancer Treat Res. 4 
2002;107: 99-118. 5 
[3] Fritsche HA, Bast RC. CA 125 in ovarian cancer: advances and controversy. Clin Chem. 6 
1998;44: 1379-80. 7 
[4] Nossov V, Amneus M, Su F et al. The early detection of ovarian cancer: from traditional 8 
methods to proteomics. Can we really do better than serum CA-125? American journal of obstetrics 9 
and gynecology. 2008;199: 215-23. 10 
[5] Jacobs I, Bast RC, Jr. The CA 125 tumour-associated antigen: a review of the literature. Hum 11 
Reprod. 1989;4: 1-12. 12 
[6] Visintin I, Feng Z, Longton G et al. Diagnostic markers for early detection of ovarian cancer. 13 
Clin Cancer Res. 2008;14: 1065-72. 14 
[7] Skates SJ, Horick N, Yu Y et al. Preoperative sensitivity and specificity for early-stage ovarian 15 
cancer when combining cancer antigen CA-125II, CA 15-3, CA 72-4, and macrophage colony-16 
stimulating factor using mixtures of multivariate normal distributions. J Clin Oncol. 2004;22: 4059-66. 17 
[8] Gorelik E, Landsittel DP, Marrangoni AM et al. Multiplexed immunobead-based cytokine 18 
profiling for early detection of ovarian cancer. Cancer Epidemiol Biomarkers Prev. 2005;14: 981-7. 19 
[9] Kabawat SE, Bast RC, Jr., Bhan AK et al. Tissue distribution of a coelomic-epithelium-related 20 
antigen recognized by the monoclonal antibody OC125. Int J Gynecol Pathol. 1983;2: 275-85. 21 
[10] Sjovall K, Nilsson B, Einhorn N. The significance of serum CA 125 elevation in malignant and 22 
nonmalignant diseases. Gynecol Oncol. 2002;85: 175-8. 23 
[11] Zhang Z, Yu Y, Xu F et al. Combining multiple serum tumor markers improves detection of 24 
stage I epithelial ovarian cancer. Gynecol Oncol. 2007;107: 526-31. 25 
[12] Moore RG, Brown AK, Miller MC et al. The use of multiple novel tumor biomarkers for the 26 
detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2008;108: 402-8. 27 
[13] Woolas RP, Xu FJ, Jacobs IJ et al. Elevation of multiple serum markers in patients with stage I 28 
ovarian cancer. J Natl Cancer Inst. 1993;85: 1748-51. 29 
[14] Mor G, Visintin I, Lai Y et al. Serum protein markers for early detection of ovarian cancer. 30 
Proc Natl Acad Sci U S A. 2005;102: 7677-82. 31 
16 
 
[15] Kozak KR, Su F, Whitelegge JP et al. Characterization of serum biomarkers for detection of 1 
early stage ovarian cancer. Proteomics. 2005;5: 4589-96. 2 
[16] Havrilesky LJ, Whitehead CM, Rubatt JM et al. Evaluation of biomarker panels for early stage 3 
ovarian cancer detection and monitoring for disease recurrence. Gynecol Oncol. 2008;110: 374-82. 4 
[17] Menon U, Gentry-Maharaj A, Hallett R et al. Sensitivity and specificity of multimodal and 5 
ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the 6 
prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet 7 
Oncol. 2009;10: 327-40. 8 
[18] Menon U, Gentry-Maharaj A, Ryan A et al. Recruitment to multicentre trials--lessons from 9 
UKCTOCS: descriptive study. BMJ (Clinical research ed. 2008;337: a2079. 10 
[19] Timms JF, Cramer R, Camuzeaux S et al. Peptides generated ex vivo from serum proteins by 11 
tumor-specific exopeptidases are not useful biomarkers in ovarian cancer. Clin Chem. 2010;56: 262-71. 12 
[20] Tiss A, Smith C, Camuzeaux S et al. Serum Peptide Profiling using MALDI Mass 13 
Spectrometry: avoiding the Pitfalls of Coated Magnetic Beads using Well-established ZipTip 14 
Technology. Proteomics. 2007;7 Suppl 1: 77-89. 15 
[21] Menon U, Skates SJ, Lewis S et al. Prospective study using the risk of ovarian cancer algorithm 16 
to screen for ovarian cancer. J Clin Oncol. 2005;23: 7919-26. 17 
[22] Myers ER, Bastian LA, Havrilesky LJ et al. Management of adnexal mass. Evid Rep Technol 18 





Table 1 Sample sets used for combined MS profiling and CA125 analysis 
 
Randomised sets – no representative sampling* 
 Training Set Test Set Total
Healthy 104 66 170
Benign 62 22 84
Malignant 38 29 67
Total 204 117 321
 
Randomised sets – with representative sampling* 
 Training Set Test Set Total
Healthy 113 57 170
Benign 55 29 84
Malignant 44 23 67
Total 213 108 321
 
* See text for further details. 
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Table 2 The performance of two peak weighted k-nearest neighbour models in comparison to the >30 
U/mL CA125 threshold model for the classification of ovarian cancer samples using the randomized 
training and blinded test set without representative sampling.  Cross-validation was performed by 
randomizing sample labels in 1,000 iterations and calculating P-values (Monte-Carlo method) for the 
randomly permutated and correctly labelled samples. 
 
 
Malignant vs. Healthy 










Sensitivity Specificity Accuracy Quality* p-value 
for 1000 
iterations 
Sensitivity Specificity Accuracy Quality* 
1 out of 2 2661 2770 97.4% 99.0% 98.6% 97.9% 0.001 100.0% 98.5% 99.0% 99.5% 
2 out of 5 972 2367 94.7% 100.0% 98.6% 96.5% 0.001 100.0% 100.0% 100.0% 100.0% 
1 out of 4 3952 1114 100.0% 92.3% 94.4% 97.4% 0.001 100.0% 86.4% 90.5% 95.5% 
CA125 >30 U/mL cut-off 94.7% 96.2% 95.8% 95.2%  100.0% 98.5% 99.0% 99.5% 
 
 
Malignant vs. Benign 










Sensitivity Specificity Accuracy Quality* p-value 
for 1000 
iterations 
Sensitivity Specificity Accuracy Quality* 
1 out of 3 4787 2367 97.4% 75.8% 84.0% 90.2% 0.001 93.1% 59.1% 78.4% 81.8% 
1 out of 4 741 3241 97.4% 75.8% 84.0% 90.2% 0.001 93.1% 54.6% 76.5% 80.3% 
2 out of 9 1467 2430 97.4% 75.8% 84.0% 90.2% 0.001 96.6% 40.9% 72.6% 78.0% 
2 out of 5 4054 3507 94.7% 85.5% 89.0% 91.7% 0.001 93.1% 63.6% 80.4% 83.3% 
CA125 >30 U/mL cut-off 94.7% 64.5% 76.0% 84.7%  100.0% 59.1% 82.4% 86.4% 
 
* Quality = (2xSensitivity + Specificity)/3 
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Table 3 The performance of two peak weighted k-nearest neighbour models in comparison to a >30 
U/mL CA125 threshold model for classification of malignant vs. benign ovarian cancer samples using 
randomized training and blinded test sets with representative sampling. Cross-validation was performed 
by randomizing sample labels in 1,000 iterations and calculating p-values (Monte-Carlo method) for 
randomly permutated and correctly labelled samples. 
 
 










Sensitivity Specificity Accuracy Quality* p-value 
for 1000 
iterations 
Sensitivity Specificity Accuracy Quality* 
1 out of 4 3263 4787 100% 76.4% 86.9% 92.1% 0.001 87.0% 69.0% 76.9% 81.0% 
4 out of 8 1742 3971 97.7% 90.9% 93.9% 95.5% 0.001 69.6% 72.4% 71.2% 70.5% 
5 out of 10 2755 2094 93.2% 92.7% 92.9% 93.0% 0.001 69.6% 86.2% 78.9% 75.1% 
CA125 >30 U/mL cut-off 97.7% 63.6% 78.8% 86.4%  95.7% 62.1% 76.9% 84.5% 
 
* Quality = (2xSensitivity + Specificity)/3 
 
 










Sensitivity Specificity Accuracy Quality* p-value 
for 1000 
iterations 
Sensitivity Specificity Accuracy Quality* 
1 out of 9 1618 4787 100.0% 69.1% 82.8% 79.4% 0.001 87.0% 58.6% 71.2% 68.1% 
4 out of 8 1742 3971 97.7% 90.9% 93.9% 93.2% 0.001 69.6% 72.4% 71.2% 71.5% 
5 out of 10 2755 2094 93.2% 92.7% 92.9% 92.9% 0.001 69.6% 86.2% 78.9% 80.7% 
2 out of 4 1520 3966 90.9% 94.6% 92.9% 93.3% 0.001 65.2% 75.9% 71.2% 72.3% 
1 out of 1 2094 1114 86.4% 98.2% 92.9% 94.2% 0.001 69.6% 79.3% 75.0% 76.1% 
CA125 >30 U/mL cut-off 97.7% 63.6% 78.8% 75.0%  95.7% 62.1% 76.9% 73.3% 
 





Figure 1 Distribution of CA125 levels in the extended sample set. 
Figure 2 A. ROC analysis of the CA125 cut-off model the classification of malignant vs. benign 
samples using the extended sample set. B. ROC analysis of the CA125 cut-off model the classification 

































































































Supplemental Data 1 
 
 
Details on the initial set of subjects, sample collection, transport, and storage 
 
Serum samples from patients were collected prior to surgery for an ovarian neoplasm 
and the diagnosis of malignant or benign ovarian neoplasm was confirmed by 
independent review of notes and histophathology reports.  The healthy volunteers had 
no significant family history of ovarian cancer and no diagnosis of a cancer during follow 
up after sample collection.  All samples were collected and processed according to a 
strict protocol as previously described (Villanueva J, Martorella AJ, Lawlor K, Philip J, 
Fleisher M, Robbins RJ, Tempst P. Serum peptidome patterns that distinguish 
metastatic thyroid carcinoma from cancer-free controls are unbiased by gender and 
age. Mol Cell Proteomics 2006;5:1840-52).  Briefly, venous blood was collected in BD 
Vacutainer (‘red top’) 10mL-tubes (Becton Dickinson, Oxford, UK; cat. no. 367985).  
Tubes were inverted 5 times and left at room temperature in a vertical position to clot for 
1 hr.  Samples were then placed on ice for no more than 2 hrs, centrifuged at 1,500 g 
for 10 min at room temperature, aliquoted into 10mL-Sarstedt tubes (Sarstedt, 
Leicester, UK; cat. no. 60.551.001) and frozen at -80°C.  All samples were then 
transported to the Institute for Women’s Health Laboratory at UCL on dry ice where they 
were thawed for 30 minutes at room temperature, mixed by gentle inversion, assayed 
for CA125 and aliquoted into bar-coded straws, re-frozen at -80°C for 24 hours and then 
transferred to liquid N2 for long-term storage.  The CA125 assays were performed 
centrally at the Institute for Women’s Health at UCL while the MS analysis was 
performed in the BioCentre at the University of Reading as described in earlier 
publications (first paper; Tiss A, Smith C, Camuzeaux S, Kabir M, Gayther S, Menon U, 
et al. Serum peptide profiling using MALDI mass spectrometry: avoiding the pitfalls of 
coated magnetic beads using well-established ZipTip technology. Proteomics 2007;7 
Suppl 1:77-89). 
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Extended sample set used for CA125 threshold model analysis 
 
 Median age Mean age SD No. 
Healthy  64.31 64.69 6.16 2236 
Benign  57.96 57.32 13.25 290 
Malignant  63.88 63.27 11.32 193 
         Stage I+II  64.41 63.52 11.87 93 
         Stage III+IV 63.85 63.04 10.84 100
 
Supplemental Data 3 
 
 
Details on the MALDI MS sample preparation, data acquisition and pre-
processing 
 
Polypeptides were enriched from 5 µL of serum sample using a semi-automated 
protocol based on reversed phase pre-packed tips (C18 ZipTips).  A CyBi™-Disk robot 
(CyBio AG, Jena, Germany) equipped with a 96-piston head for 25µL-tips was adapted 
and used for this purpose.  After C18 ZipTip purification, enriched polypeptides were 
eluted from the ZipTips, mixed with CHCA matrix and spotted in four replicates of 0.8µL 
onto a 600µm-AnchorChip™ target plate (Bruker Daltonics) and allowed to dry at room 
temperature. 
 
Mass spectrometric serum polypeptide profiles were acquired on an Ultraflex II MALDI-
TOF/TOF mass spectrometer (Bruker Daltonics, Coventry, UK) in the linear mode.  The 
overall performance of the mass spectrometer was thoroughly checked every 2-3 weeks 
using peptide standards and a tryptic digest of bovine serum albumin.  In addition, a 
commercial human serum standard (Sigma, # S7023) (previously prepared using the 
ZipTip protocol, aliquotted and frozen) was used prior to each run for a general systems 
check.  Using this standard serum sample, the resolution and intensity of five major 
peaks across the mass range of 1,800 to 8,200 Da were checked against previously 
obtained data and, if necessary, the laser power was adjusted to keep the intensity and 
resolution of these peaks within their predetermined range of values of ± 2 SD. 
All samples were analysed at least in triplicate on separate days.  The same 
commercial, pooled serum standard as above was freshly prepared 3 times within each 
batch of serum samples as an internal quality control to assess intra- and inter-run 
variations.  ClinProTools software V2.1 (Bruker Daltonics) was used for this purpose 
and allowed to calculate the coefficient of variation (CV) of each of the individual peak 
areas (more than 100 peaks per spectrum) as well as the mean CV and standard 
deviation for all of the peaks within the same run or between runs. 
Furthermore, the following criteria were checked for each sample:  (1) for each run at 
least 3 out of the 4 spot replicates contained 1,000 laser shots and were not rejected on 
grounds of low analyte signal or excessively high matrix signal and (2) at least 2 
different runs satisfied condition (1).  However, all samples yielded sufficiently 
reproducible spectra and none of the samples was excluded. 
 
More information can be found in the SOP below: 
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2.1. Collecting blood samples and preparing serum 




2. Gently  invert the tube five times to mix the clot activator with the blood.   Allow blood to 
clot for 1 h at room temperature keeping the tube in the upright position. 






6. Transfer  the  serum  (upper  phase)  to  the  appropriately  labelled  straws.    The  volume  of 
serum per straw should be approximately 500 µl. 
7. Immediately store all samples at –80 °C. 
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8. Transport samples to the MS  laboratory on dry  ice.   On arrival they must  immediately be 
stored at –80 °C again. 
NOTE:  Avoid freeze‐thaw cycles at all steps because they induce proteolysis (in the absence of anti‐proteases) 
and  the  precipitation  of  peptides/proteins.
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2.2.1. Preparations for sub-sampling 
WARNING:    All  sub‐sampling  must  be  carried  out  in  an  adequate  safety  cabinet.    Equipment  and 
consumables used  for  the purpose of  sub‐sampling  should be housed  inside  the  cabinet and  should be 










20  × 200µl‐PCR  tubes.   A 96‐well microtitre plate  (parent plate)  is used  for up  to 90  sample 
aliquots to be run on a liquid handling robot.  The remaining 6 wells are used for control samples 
as detailed  later.   All sample vials, tubes and plates must be kept on wet  ice during the entire 
sub‐sampling procedure. 
 








piece  in  the Virkon® solution.   Wash  the scissors by spraying  the blades with ethanol 
from a wash bottle. 
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12. Lift the straw slightly to allow the thawed serum to drain  into the PCR tube.   Use the 
pipettor with a tip set at 50 µl to blow air through the tube from the top down, in order 
to expel  the  last  few drops of  serum  into  the  tube.   Place  the empty  straw  into  the 
Virkon® solution.  Use the pipettor with the same tip still attached to mix the contents 
















3 of  the 6 empty wells on  the microtitre plate.   This  standard  serum will be used as 
initial control for the whole run.  The 3 remaining wells are left empty so that there are 
free  spots  on  the  MALDI  target  plate.    A  post‐preparation  control  sample  is  later 
spotted onto these empty sample spots (see SST solution, step 31). 
NOTE:   Serum must be kept on  ice during all aliquotting steps.   Prior to use, the standard serum sample 
should be aliquotted at 200 and 500 µl into PCR tubes and stored at ‐80 °C until required. 
 
2.2.3. Sub-sampling from parent microtitre plate 
NOTE:    The  following  example  of  sub‐sampling  utilises  a  CyBi™‐Disk  robot  (CyBio,  Northern  Europe) 
equipped with a 96‐piston head for 25µl‐tips and 10 microtitre plate positions and specifically set‐up for 
this task (see Annexe 1).  Thus some steps will most likely differ when using another liquid handling robot. 
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19. Open  the  customised method  “Sub‐sampling”  from  the CyBi™  control  software.   This 
































Mix  and  aliquot  at 4 µl.    Store  the  aliquots  at  ‐20°C  (see Annexe 3  for  a  list of PCS 
components). 
31. System Suitability Test (SST) solutions:  A 96‐well plate containing 5 µl of the standard 
serum  sample  in each well  is prepared using  the protocol detailed  in section 2.4,  i.e. 
steps 32‐63, for 96 samples.  The 96 eluates are pooled, mixed and then aliquotted at 4 
µl. Aliquots are stored at ‐80 °C until required. 
NOTE:   SST solutions are used as controls  to check both  the  reproducibility of performance of  the mass 
spectrometer (see Section 2.5.1, step 77, and Annexe 6) and the sample preparation (see Section 2.5.2.1). 
 
2.4. Extracting polypeptides from serum 






2.4.1. Preliminary preparations 
32. Turn on the CyBi™‐Disk robot. 
33. If the ambient relative humidity  is  less than 50%,  increase relative humidity to around 
50%,  e.g.  turn  on  a  humidifier,  set  it  to  50%,  turn  on  a  circulating  fan  in  the  CyBi™ 
cabinet and close the cabinet door. 
34. Ensure  the  solvents and other  solutions are  less  than 1 week old and check  that  the 










NOTE:   Ensure  that all details of  the sample preparation are  recorded  in  the  lab book, especially noting any 
deviation from this protocol and important observations made during the procedure. 
 

























2.4.4. Preparation of plates, prior to extraction 





2.4.5. Sample clean-up and MALDI sample preparation 
55. Record  the  batch  name  of  the  sample  (plate)  to  be  run  (including  the  date  of 
preparation) on the plate plan and make a copy of the plan. 










































69. On  both  MALDI  target  plates  spot  0.8  µl  of  the  mixture  onto  each  of  10  random 
calibrant  positions.    These  spots  are  used  for  external  calibration  of  the  MS.    The 
















2.5. MALDI MS data acquisition and analysis 
 
2.5.1. Data acquisition 
 
NOTE:    This  protocol  uses  an  Ultraflex  II  MALDI‐TOF/TOF  instrument  (Bruker  Daltonics)  controlled  by 
FlexControl software v.3.0 (Bruker Daltonics) with samples spotted on AnchorChip™ target plates having 384 
anchors of 600µm diameter. 
74. Open  the  FlexControl  software  and  load  optimised  FlexControl  and  AutoXecute 
methods (see Annexes 4 and 5 for examples as used in the BioCentre at the University 
of  Reading).    These  MALDI‐TOF  settings  must  be  optimised  for  each  individual 
instrument. 
75. Take  the  first  target  plate  from  the  robot  and  insert  it  into  the  MALDI‐TOF  mass 
spectrometer.   The plate should be analysed by  the mass spectrometer within 2 h of 
MALDI sample spotting.  Keep the second target plate covered for possible later use. 




The  signal‐to‐noise  ratio  and  resolution  of  five well‐selected  peaks  should  be within 
their predetermined range of values of ± 2 SD (see Annexe 6).  If this is not the case, re‐
adjust  the  laser power accordingly and collect spectra  from another SST spot  to  fulfil 




78. Load  the  correct  autoXsequence  file  (containing  the  names  and  positions  of  each 
sample on the target as well as the file name and path where the spectra will be saved 
on the hard disk).   This  file can be generated by using an Excel spreadsheet  from the 



















81. Within  the  directory  containing  the MALDI  files,  create  a  sub‐directory  and  name  it 
“1000shots”.    Transfer  any  spectra  that  gave  less  than  1000  shots  to  this  directory.  
These spectra are excluded from further data processing and analysis. 
82. Open  the ClinProTools program  to give a display with  four quadrants.   From  the File 
tab,  select  “Open  Model  Generation  Class”  and  browse  to  find  the  sub‐directory 
containing all spectra files of the SST samples.   Each of the SST spectra  is then  loaded 
into the software.   Individual or average spectra are depicted  in the top  left quadrant, 
and  all  of  the  loaded  spectra  are  depicted  in  a  pseudo‐gel  view  in  the  bottom  left 
quadrant. 




83. Select  “Open Model Generation  Class”  again  and  this  time  browse  to  find  the  sub‐
directory containing all the spectra given by the standard serum samples prepared with 
the  batch  of  real  samples.    These  spectra  will  be  depicted  in  the  pseudo‐gel  view 
alongside  the  spectra of  the  SST  samples,  thus  allowing  a  visual  comparison of  their 
spectra.   The 2 classes should give virtually  identical spectra,  in which case the overall 
preparation of the batch of samples is deemed acceptable.  If the spectra are markedly 
different then further investigation will be needed to determine the cause. 
84. Each  sample  preparation  should  yield  a  maximum  of  4  spectra,  depending  on  the 
number of spectra excluded at step 81 (if any).  The spectra for each individual sample 
are  loaded  as  a  class  into  ClinProTools,  and  are  visually  inspected  to  determine  any 






85. ClinProTools  can  also  be  used  to  identify  peaks  that  are  significantly  different  (in 




86. ClinProTools  is  just  one  example  of  the  large  number  of  different  bioinformatics 
programs that can be used for the more detailed analysis of the data.  For compatibility 
with  these programs spectra can be exported as  tab‐separated  text  files  that contain 
the mass  list with the corresponding  intensities.   This export facility  is available within 
FlexAnalysis. 





















3  Child 96‐well MTP  384‐well MTP ACN,  384‐well MTP 
4  Child 96‐well MTP  384‐well MTP 0.1% TFA,  384‐well MTP




9  Child 96‐well MTP  Bulk reservoir Bulk reservoir Empty* 
10  Child 96‐well MTP  MALDI target 2 























































































































m/z Signal/Noise Resolution 










1808.82 1919 1214 2624 184 177 190 
2981.54 2841 2399 3283 234 226 241 
5003.29 4159 3330 4988 293 286 300 
6447.50 959 749 1169 261 224 298 
8126.35 1344 1073 1616 146 114 177 
 
 
 
 
 
